Navigation Links
Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S.
Date:10/8/2010

Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S. -- ABBOTT PARK, Ill., Oct. 8 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Product Recalls Click to view news release full screen  

Abbott to Voluntarily Withdraw Meridia® (Sibutramine) in the U.S.

 

ABBOTT PARK, Ill., Oct. 8 /PRNewswire/ -- Abbott (NYSE: ABT) will voluntarily withdraw Meridia® (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).The FDA's request is based primarily on the results of the SCOUT (Sibutramine Cardiovascular OUTcome Trial) study, an approximately 10,000 patient, 6-year study requested by European regulatory authorities as a post-marketing commitment to evaluate cardiovascular safety in high-risk patients.  The majority of these patients had underlying cardiovascular disease and were not eligible to receive sibutramine under the current labeling.

The SCOUT results are in contrast to the vast body of sibutramine data for the on-label patient population, including 46 controlled clinical trials and more than 6 million patient years of use accumulated over 13 years during which the product has been available.  These data fail to confirm the excess cardiovascular risk found in the SCOUT study.

The voluntary withdrawal of sibutramine in the U.S. follows an 11-month process, beginning in November 2009, when Abbott promptly notified FDA of the SCOUT preliminary results immediately after receiving those results.  The European Medicines Agency (EMA) suspended marketing authorization for all anti-obesity medicines containing sibutramine in January 2010.

Abbott submitted label changes to FDA in January 2010 to further ensure appropriate use of the product based on the preliminary SCOUT findings.  Over the course of the next nine months, Abbott conducted and provided numerous analyses to FDA and other global regulatory authorities for the purpose of determining the applicability of the SCOUT data to the approved patient population.  These analyses confirmed the appropriateness of the current label: that people with preexisting cardiovascular disease should not take the medication.  These analyses also confirmed there was no excess risk in the approved patient population.

Abbott provided a comprehensive review of these analyses at the Sept. 15, 2010, public advisory panel with 16 experts selected by FDA.  That panel reviewed and debated the available data on sibutramine.  The results of the panel's deliberations – an 8-8 split decision with eight advisors voting in favor of enhanced labeling and risk management activities compared to eight advisors in favor of withdrawal – highlights the complexity of the scientific debate and the different interpretations of the data, even by independent experts.

Abbott believes sibutramine has a positive risk/benefit profile in the approved patient population, but will comply with the FDA's request.  

Patients should discontinue use of sibutramine and consult their physician for alternatives.  Patients can call Abbott's medical information line in the U.S. at 1-866-257-8909 or visit www.sibutramine.com.

Abbott is having ongoing discussions with regulatory authorities in countries where sibutramine is marketed and anticipates concluding those discussions in the coming days.

The following information reflects current product labeling and has always been provided to health care providers and in public communications about Meridia.

UseMeridia (sibutramine hydrochloride monohydrate) is a prescription medicine used to help overweight or obese people lose weight.  Meridia should be used together with a low-calorie diet.

Important Safety InformationMeridia is not for everyone.  People should not take Meridia if they:

  • have or have had, heart problems, including:
  • heart attack
  • chest pain
  • heart failure
  • fast or irregular heart beat
  • hardening of their arteries or other blood vessels
  • poor circulation in their legs
  • uncontrolled or poorly controlled blood pressure (above 145/90).
  • are over age 65.
  • are taking or have taken a type of medicine used to treat depression called a monoamine oxidase inhibitor (MAOI) in the past two weeks.  MAOIs should not be taken for at least two weeks before using Meridia.  MAOIs should not be taken for at least two weeks after stopping Meridia.  People should ask their doctor or pharmacist if they are not sure if any of their medicines are MAOIs.
  • have an eating problem called anorexia nervosa or bulimia nervosa.
  • are taking certain other weight loss medicines.
  • are allergic to sibutramine hydrochloride monohydrate or any other ingredients in Meridia.

  • Meridia can cause serious side effects including large increases in blood pressure or heart rate (pulse) in some people.  Patients should call their doctor right away if they check their blood pressure and it is higher than normal for them, or if they have symptoms of high blood pressure such as headache, dizziness or blurred vision.

    Before starting Meridia, patients should have their blood pressure and heart rate checked by their doctor.  Their doctor should continue checking their blood pressure regularly while taking Meridia.  It is important that patients have regular check-ups with their doctor while they are taking Meridia.

    People should not take Meridia if they have severe liver or kidney disease, are pregnant or planning to get pregnant, or if they are nursing.

    Patients should tell their doctor if they have or ever have had glaucoma, kidney or liver problems, seizures, bleeding problems, gallstones or depression, are pregnant or planning to become pregnant, or are breastfeeding.

    Using Meridia with certain other medicines may affect how Meridia or the other medicines work.  Patients should tell their doctor about all the medications they take, including prescription and non-prescription medicines, vitamins and herbal supplements.  Patients should especially tell their doctor if they take: a monoamine oxidase inhibitor (MAOI) medicine, other weight loss medicines, cough and cold medicines, migraine headache medicines, medicines used to treat depression, narcotic pain medications, lithium, tryptophan, or medicines that thin the blood.

    Meridia may cause serious side effects, including:

  • Serotonin syndrome, which may happen when people take Meridia with certain other medicines that affect a brain chemical called serotonin.  Patients should not take other medicines with Meridia unless their doctor has told them to.  Patients should get medical help right away if they have any of the following symptoms:
  • feel weak, restless, confused or anxious
  • lose consciousness (faint)
  • have a fever, vomiting, sweating, shivering or shaking
  • have a fast heart beat
  • seizures (convulsions, fits).
  • bleeding.  Bleeding may happen if patients have a condition that causes bleeding or if they take a blood thinning medicine.

  • Certain weight loss medicines have a rare but life-threatening problem that affects blood pressure in the lungs (pulmonary hypertension).  It is not known if Meridia may cause this problem.  Patients should call their doctor right away if they have new or worsening shortness of breath.

    The most common side effects include dry mouth, loss of appetite, trouble sleeping, constipation and headache.

    Patients should not drive, operate heavy machinery or do other dangerous activities until they know how Meridia affects them.

    Never give Meridia to anyone else because it may cause death or harm them.  Selling or giving away this medicine is against the law.

    This is some of the most important information to know about Meridia.  For more information, patients should talk with their health care provider.

    About AbbottAbbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.  

    Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


    '/>"/>

    SOURCE Abbott
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia
    2. Abbott Named One of the Top Employers in the Biotech and Pharmaceutical Industry by Science Magazine
    3. Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution
    4. Abbotts XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
    5. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
    6. Abbotts Fully Bioresorbable Vascular Scaffold Technology Continues to Demonstrate Strong Clinical Results
    7. The Deal Names Abbott Top Dealmaker for Third Consecutive Year
    8. Abbott Declares 347th Consecutive Quarterly Dividend
    9. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
    10. Abbott Statement on the FDA Advisory Committee Recommendation on Sibutramine
    11. Abbott Honored for Workplace Leadership for the Tenth Consecutive Year by Working Mother Magazine
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2017)... , Jan. 23, 2017  Allergan plc, (NYSE: ... continued support of the International Headache Academy (IHA). Designed to ... and research scientists, IHA offers a three-day, intensive overview on ... Allergan has been the sole sponsor since the inception of ... and iHEAD in Europe in 2014. ...
    (Date:1/23/2017)... 23, 2017 Ahead of today,s trading session, ... they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... relative laggards on Friday, January 20 th , 2017, down on ... reports on these stocks now at: ...
    (Date:1/23/2017)... SAN DIEGO , 23 janvier 2017  ResMed ... Winter Haven , Floride) ont annoncé aujourd,hui qu,ils se ... les litiges existants entre les parties. BMC et 3B ... de paiements de droits à ResMed, et ResMed effectuera ... à 3B pour clore le litige de Floride entre ...
    Breaking Medicine Technology:
    (Date:1/24/2017)... TEXAS (PRWEB) , ... January ... ... Texas-based healthcare and clinical research networking-technology company founded by patient survivors, today ... innovative BlueCloud® business model, networking technologies and patient-inspired initiatives. , Like ...
    (Date:1/24/2017)... ... 23, 2017 , ... United Nations Foundation President and CEO ... City Policy, also known as the Global Gag Rule, last enacted in 2001. ... non-governmental organizations from receiving any U.S. foreign assistance for family planning if they ...
    (Date:1/24/2017)... , ... January 23, 2017 , ... ... of a new plugin that allows sleep centers to automatically connect and initialize ... (SDI)—is a thin client browser plugin is quickly installed on first use and ...
    (Date:1/23/2017)... ... January 23, 2017 , ... Ultimate Medical ... Education Summit to be held March 23-25, 2017 in Tampa, and reminded educators ... , The keynote speakers include Dr. Michelle R. Weise, executive director of the ...
    (Date:1/23/2017)... Grants Pass, OR (PRWEB) , ... January 23, 2017 , ... ... disease, took to the air to educate listeners about the benefits of making new ... in the U.S.,” Kleyne said, “it’s appropriate that we expect water infrastructure to become ...
    Breaking Medicine News(10 mins):